#BEGIN_DRUGCARD DB03585

# AHFS_Codes:
Not Available

# ATC_Codes:
M01AA03
M02AA04
S01BC02

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Aradinum
Artroflog
Butaflogin
Butanora
Butanova
Butapirone
Butazonic
Butilene
Californit
Cinophen-n
Crovaril
Deflogin
Etrozolidina
Flamaril
Flanaril
Flegmostam
Flogal
Floghene
Flogistin
Flogitolo
Flogodin
Flogoril
Flogostop
Flopirina
Frabel
Genal
Idrobutazina
Infamil
Infammil
Ipabutona
Iridil
Isobutazina
Isobutil
Metabolite I
Mysite
Neo-farmadol
Neofen
Offitril
Optimal
Oxalid
Oxazolidin
Oxazolidin-geigy
Oxazolioin
Oxi-fenibutol
Oxibutol
Oxybuton
Oxyphentamin
Pirabutina
Piraflogin
Poliflogil
Portoril
Rapostan
Remazin
Reumox
Reunabutal
Rumapax
Tandacote
Tandalgesic
Tandearil
Tanderal
Tanderil
Telidac
Telidal
Tendearil
Valioil
Visubutina

# CAS_Registry_Number:
129-20-4

# ChEBI_ID:
Not Available

# Chemical_Formula:
C19H20N2O3

# Chemical_IUPAC_Name:
4-butyl-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Oxyphenbutazone was withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression.

# Dosage_Forms:
Not Available

# Drug_Category:
Phospholipase A2 Vrv-Pl-Viiia inhibitor

# Drug_Interactions:
Acenocoumarol	The NSAID, oxyphenbutazone, may increase the anticoagulant effect of acenocoumarol.
Alendronate	Increased risk of gastric toxicity
Anisindione	The NSAID, oxyphenbutazone, may increase the anticoagulant effect of anisindione.
Dicumarol	The NSAID, oxyphenbutazone, may increase the anticoagulant effect of dicumarol.
Ethotoin	The NSAID, oxyphenbutazone, may increase the hydantoin effect of ethotoin.
Fosphenytoin	The NSAID, oxphenbutazone, may increase the hydantoin effect of fosphenytoin.
Mephenytoin	The NSAID, oxyphenbutazone, may increase the hydantoin effect of mephenytoin.
Phenytoin	The NSAID, oxphenbutazone, may increase the therapeutic and adverse effects of phenytoin.
Warfarin	The NSAID, oxyphenbutazone, may increase the anticoagulant effect of warfarin.

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule
Withdrawn

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
2.72

# Experimental_Logs:
-3.73

# Experimental_Water_Solubility:
60 mg/L (at 30 °C)

# Food_Interactions:
Take with food to reduce irritation.

# GenBank_ID:
Not Available

# Generic_Name:
Oxyphenbutazone

# HET_ID:
OPB

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C19H20N2O3/c1-2-3-9-17-18(23)20(14-7-5-4-6-8-14)21(19(17)24)15-10-12-16(22)13-11-15/h4-8,10-13,17,22H,2-3,9H2,1H3

# InChI_Key:
InChIKey=HFHZKZSRXITVMK-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3585

# Mechanism_Of_Action:
Not Available

# Melting_Point:
96 °C

# Molecular_Weight_Avg:
324.3737

# Molecular_Weight_Mono:
324.147392516

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1Q7A

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA450750

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
2.79

# Predicted_LogS:
-3.1

# Predicted_Water_Solubility:
2.56e-01 g/l

# Primary_Accession_No:
DB03585

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
4641

# PubChem_Substance_ID:
46507285

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02440

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CCCCC1C(=O)N(N(C1=O)C1=CC=C(O)C=C1)C1=CC=CC=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
1-(p-Hydroxyphenyl)-2-phenyl-4-butyl-3,5-pyrazolidinedione
1-Phenyl-2-(p-hydroxyphenyl)-3,5-dioxo-4-butylpyrazolidine
1-p-Hydroxyphenyl-2-phenyl-3,5-dioxo-4-N-butylpyrazolidine
3,5-Pyrazolidinedione, 4-butyl-1-(4-hydroxyphenyl)-2-phenyl
4-Butyl-1-(4-hydroxyphenyl)-2-phenyl-3,5-pyrazolidinedione
4-Butyl-1-(p-hydroxyphenyl)-2-phenyl-3,5-pyrazolidinedione
4-Butyl-2-(4-hydroxyphenyl)-1-phenyl-3,5-dioxopyrazolidine
4-Butyl-2-(p-hydroxyphenyl)-1-phenyl-3,5-pyrazolidinedione
Hydroxyphenylbutazon
OPB
Ossifenbutazone [dcit]
Oxifenbutazona [inn-spanish]
Oxifenylbutazon
Oxiphenbutazone
Oxiphenbutazonum
Oxyphenbutazonum [inn-latin]
Oxyphenobutazone
Oxyphenylbutazone
P-hydroxyphenylbutazone
P-oxyphenylbutazone
Usaf Ge-14

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:24 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Oxyphenbutazone

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Secreted

# Drug_Target_1_Chromosome_Location:
1

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
AF189279

# Drug_Target_1_GenBank_ID_Protein:
7108923

# Drug_Target_1_GeneCard_ID:
PLA2G2E

# Drug_Target_1_Gene_Name:
PLA2G2E

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Involved in calcium ion binding

# Drug_Target_1_General_References:
10681567	Suzuki N, Ishizaki J, Yokota Y, Higashino K, Ono T, Ikeda M, Fujii N, Kawamoto K, Hanasaki K: Structures, enzymatic properties, and expression of novel human and mouse secretory phospholipase A(2)s. J Biol Chem. 2000 Feb 25;275(8):5785-93.
16710414	Gregory SG, Barlow KF, McLay KE, Kaul R, Swarbreck D, Dunham A, Scott CE, Howe KL, Woodfine K, Spencer CC, Jones MC, Gillson C, Searle S, Zhou Y, Kokocinski F, McDonald L, Evans R, Phillips K, Atkinson A, Cooper R, Jones C, Hall RE, Andrews TD, Lloyd C, Ainscough R, Almeida JP, Ambrose KD, Anderson F, Andrew RW, Ashwell RI, Aubin K, Babbage AK, Bagguley CL, Bailey J, Beasley H, Bethel G, Bird CP, Bray-Allen S, Brown JY, Brown AJ, Buckley D, Burton J, Bye J, Carder C, Chapman JC, Clark SY, Clarke G, Clee C, Cobley V, Collier RE, Corby N, Coville GJ, Davies J, Deadman R, Dunn M, Earthrowl M, Ellington AG, Errington H, Frankish A, Frankland J, French L, Garner P, Garnett J, Gay L, Ghori MR, Gibson R, Gilby LM, Gillett W, Glithero RJ, Grafham DV, Griffiths C, Griffiths-Jones S, Grocock R, Hammond S, Harrison ES, Hart E, Haugen E, Heath PD, Holmes S, Holt K, Howden PJ, Hunt AR, Hunt SE, Hunter G, Isherwood J, James R, Johnson C, Johnson D, Joy A, Kay M, Kershaw JK, Kibukawa M, Kimberley AM, King A, Knights AJ, Lad H, Laird G, Lawlor S, Leongamornlert DA, Lloyd DM, Loveland J, Lovell J, Lush MJ, Lyne R, Martin S, Mashreghi-Mohammadi M, Matthews L, Matthews NS, McLaren S, Milne S, Mistry S, Moore MJ, Nickerson T, O'Dell CN, Oliver K, Palmeiri A, Palmer SA, Parker A, Patel D, Pearce AV, Peck AI, Pelan S, Phelps K, Phillimore BJ, Plumb R, Rajan J, Raymond C, Rouse G, Saenphimmachak C, Sehra HK, Sheridan E, Shownkeen R, Sims S, Skuce CD, Smith M, Steward C, Subramanian S, Sycamore N, Tracey A, Tromans A, Van Helmond Z, Wall M, Wallis JM, White S, Whitehead SL, Wilkinson JE, Willey DL, Williams H, Wilming L, Wray PW, Wu Z, Coulson A, Vaudin M, Sulston JE, Durbin R, Hubbard T, Wooster R, Dunham I, Carter NP, McVean G, Ross MT, Harrow J, Olson MV, Beck S, Rogers J, Bentley DR, Banerjee R, Bryant SP, Burford DC, Burrill WD, Clegg SM, Dhami P, Dovey O, Faulkner LM, Gribble SM, Langford CF, Pandian RD, Porter KM, Prigmore E: The DNA sequence and biological annotation of human chromosome 1. Nature. 2006 May 18;441(7091):315-21.

# Drug_Target_1_HGNC_ID:
GNC:13414

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
6270

# Drug_Target_1_Locus:
1p36.13

# Drug_Target_1_Molecular_Weight:
15988.5

# Drug_Target_1_Name:
Group IIE secretory phospholipase A2

# Drug_Target_1_Number_of_Residues:
142

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00068	Phospholip_A2_1

# Drug_Target_1_Protein_Sequence:
>Group IIE secretory phospholipase A2
MKSPHVLVFLCLLVALVTGNLVQFGVMIEKMTGKSALQYNDYGCYCGIGGSHWPVDQTDW
CCHAHDCCYGRLEKLGCEPKLEKYLFSVSERGIFCAGRTTCQRLTCECDKRAALCFRRNL
GTYNRKYAHYPNKLCTGPTPPC

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-19

# Drug_Target_1_Specific_Function:
PA2 catalyzes the calcium-dependent hydrolysis of the 2- acyl groups in 3-sn-phosphoglycerides. Has a preference for arachidonic-containing phospholipids

# Drug_Target_1_SwissProt_ID:
Q9NZK7

# Drug_Target_1_SwissProt_Name:
PA2GE_HUMAN

# Drug_Target_1_Synonyms:
GIIE sPLA2
Phosphatidylcholine 2-acylhydrolase GIIE
sPLA(2)-IIE

# Drug_Target_1_Theoretical_pI:
8.28

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB03585
